Journal
CURRENT PHARMACEUTICAL DESIGN
Volume 21, Issue 36, Pages 5187-5197Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612821666150923095618
Keywords
Active targeting; controlled drug delivery; osteosarcoma therapy; passive targeting; polymeric nanocarriers
Categories
Funding
- National Natural Science Foundation of China [51303174, 51321062, 51233004, 51390484, 51273196, 51203153]
- Scientific Development Program of Jilin Province [20140520050JH]
Ask authors/readers for more resources
Osteosarcoma (OS) is one of the most serious malignancies along with a high incidence in children and teenagers. Although the neoadjuvant chemotherapy of OS has made great progress and prolongs the five-year survival rates of patients to some extent, drugs are restrained from clinical application due to the unsatisfactory efficacy and severe side effects, especially for the systemic therapy through intravenous injection. The polymeric nanoparticles as anti-cancer drug nanocarriers make OS treatment more promising and effective. Specifically, various polymeric nanoparticles have been developed to overcome the difficulties in targeting delivery of drugs to OS tissue and/or cells through passive and/or active strategies. This review presents an overview on the development of polymeric nanoparticles for anti-cancer drug delivery in OS treatment, and briefly describes the challenge and opportunity for future development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available